Press Release June 16, 2022

HIBio Strikes Exclusive License with Morphosys to Felzartamab, an Anti-CD38 Antibody, and MOR210, an Anti-C5aR1 Antibody

The Life Sciences team advised HIBio on its equity participation agreement and license agreements with MorphoSys AG (FSE: MOR; NASDAQ: MOR). Under the agreements, HIBio is granted exclusive worldwide rights to develop and commercialize MorphoSys’ felzartamab, and MOR210, with the exception of Greater China for felzartamab and Greater China and South Korea for MOR210. MorphoSys will receive a 15% equity stake in HIBio and up to $1 billion in milestone payments across programs, plus single- to low double-digit royalties on net sales.

Human Immunology Biosciences (HIBio) is a biotechnology company focused on discovering and developing precision medicines for people suffering from autoimmune and inflammatory diseases, backed by ARCH Venture Partners and Monograph Capital.

MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases.

The Goodwin team was led by Sarah Stoiber, Laurie Burlingame and Kingsley Taft, and included Amarilice Young, Ryan Donahoe and Gaebriella DeLisle. (Corporate), Simone Waterbury (Antitrust), Kevin Kabler and Pavel Puzerey (IP), Alex Varond (Regulatory) and Dan Karelitz (Tax).

For more details, read the press release and articles in Endpoints News and BioSpace.